	US 11,859,001 B2
	IL12RB1-Binding molecules and methods of use
Robert Kastelein, Menlo Park, CA (US); Deepti Rokkam, Menlo Park, CA (US); Patrick J. Lupardus, Menlo Park, CA (US); and Sandro Vivona, Menlo Park, CA (US)
Assigned to Synthekine, Inc., Menlo Park, CA (US)
Appl. No. 18/017,282
Filed by SYNTHEKINE, INC., Menlo Park, CA (US); and Sandro Vivona, Menlo Park, CA (US)
PCT Filed Aug. 5, 2021, PCT No. PCT/US2021/044674 § 371(c)(1), (2) Date Jan. 20, 2023, PCT Pub. No. WO2022/031929, PCT Pub. Date Feb. 10, 2022.
Claims priority of provisional application 63/135,884, filed on Jan. 11, 2021.
Claims priority of provisional application 63/078,745, filed on Sep. 15, 2020.
Claims priority of provisional application 63/061,562, filed on Aug. 5, 2020.
Prior Publication US 2023/0272093 A1, Aug. 31, 2023
Int. Cl. C07K 16/24 (2006.01); C07K 16/28 (2006.01); C07K 14/715 (2006.01); C12N 15/63 (2006.01)

CPC C07K 16/2866 (2013.01) [C07K 14/7155 (2013.01); C12N 15/63 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01)]

14 Claims

1. An IL12Rb1 binding molecule that specifically binds to the extracellular domain of IL12Rb1, wherein the IL12Rb1 binding molecule comprises a single domain antibody (sdAb), and wherein the sdAb comprises:

(1) a complementary determining region 1 (CDR1) comprising the sequence of SEQ ID NO:24, a CDR2 comprising the sequence of SEQ ID NO:25, and a CDR3 comprising the sequence of SEQ ID NO:26;

(2) a CDR1 comprising the sequence of SEQ ID NO:87, a CDR2 comprising the sequence of SEQ ID NO:88, and a CDR3 comprising the sequence of SEQ ID NO:89; or

(3) a CDR1 comprising the sequence of SEQ ID NO:75, a CDR2 comprising the sequence of SEQ ID NO:76, and a CDR3 comprising the sequence of SEQ ID NO:77.